A Systems Genetics Approach Identifies CXCL14, ITGAX, and LPCAT2 as Novel Aggressive Prostate Cancer Susceptibility Genes

@article{Williams2014ASG,
  title={A Systems Genetics Approach Identifies CXCL14, ITGAX, and LPCAT2 as Novel Aggressive Prostate Cancer Susceptibility Genes},
  author={Kendra A. Williams and Minnkyong Lee and Ying Hu and Jonathan Andreas and Shashank J. Patel and Suiyuan Zhang and Peter S. Chines and Abdel G. Elkahloun and Settara C. Chandrasekharappa and J. Silvio Gutkind and Alfredo A. Molinolo and Nigel P. S. Crawford},
  journal={PLoS Genetics},
  year={2014},
  volume={10}
}
Although prostate cancer typically runs an indolent course, a subset of men develop aggressive, fatal forms of this disease. We hypothesize that germline variation modulates susceptibility to aggressive prostate cancer. The goal of this work is to identify susceptibility genes using the C57BL/6-Tg(TRAMP)8247Ng/J (TRAMP) mouse model of neuroendocrine prostate cancer. Quantitative trait locus (QTL) mapping was performed in transgene-positive (TRAMPxNOD/ShiLtJ) F2 intercross males (n = 228), which… Expand
GNL3 and SKA3 are novel prostate cancer metastasis susceptibility genes
TLDR
This novel approach demonstrates how mouse models can be used to identify metastasis susceptibility genes, and gives new insight into the molecular mechanisms of fatal PC. Expand
Correction: A Systems Genetics Approach Identifies CXCL14, ITGAX, and LPCAT2 as Novel Aggressive Prostate Cancer Susceptibility Genes
  • Medicine
  • PLoS genetics
  • 2015
TLDR
SNPs in three of the five genes associated with poor clinical outcomes in TCGA (Provisional) and GSE21032 prostate cancer gene expression datasets (CXCL14, ITGAX, and LPCAT2) were all associated with aggressive prostate cancer, and haplotypes in LD with these three QTL candidate genes were associated with clinical markers of prostate cancer aggressiveness. Expand
Modifier locus mapping of a transgenic F2 mouse population identifies CCDC115 as a novel aggressive prostate cancer modifier gene in humans
TLDR
It is demonstrated how modifier locus mapping in mouse models of PC, coupled with in silico analyses of human PC datasets, can reveal novel germline modifier genes of aggressive PC. Expand
Mapping Complex Traits in a Diversity Outbred F1 Mouse Population Identifies Germline Modifiers of Metastasis in Human Prostate Cancer.
TLDR
Crossing a dominant, penetrant mouse model of prostate cancer to Diversity Outbred mice demonstrates how well-characterized genetic variation in mice can be harnessed in conjunction with systems genetics approaches to identify and characterize germline modifiers of human disease processes. Expand
Prostate cancer susceptibility gene HIST1H1A is a modulator of androgen receptor signaling and epithelial to mesenchymal transition
TLDR
Assay for Transposase-Accessible Chromatin (ATAC-seq), used to assess chromatin compaction and thus the transcriptional availability of individual genomic regions, demonstrated that H1.1 plays a prominent role in modulating Wnt signaling pathway genes, which are implicated in prostate tumorigenesis. Expand
Transcriptome analyses identify a metabolic gene signature indicative of dedifferentiation of papillary thyroid cancer.
  • Ben Ma, Hongyi Jiang, +11 authors Qinghai Ji
  • Medicine, Biology
  • The Journal of clinical endocrinology and metabolism
  • 2019
TLDR
The findings suggest metabolic deregulations mediate dedifferentiation of PTC, and the metabolic gene signature can be used as a biomarker for DDTC. Expand
Aicardi-Gouti è res syndrome gene Rnaseh 2 c is a metastasis susceptibility gene in breast cancer
Breast cancer is the second leading cause of cancer-related deaths in the United States, with the majority of these deaths due to metastatic lesions rather than the primary tumor. Thus, a betterExpand
Necdin is a breast cancer metastasis suppressor that regulates the transcription of c-Myc
TLDR
Haplotype analysis in a well-characterized breast cancer cohort revealed thatNDN germline variation is associated with both NDN expression levels and patient outcome, and ChIP assays demonstrate that NDN and the T50C allele regulate gene expression and metastasis efficiency. Expand
Aicardi-Goutières Syndrome gene Rnaseh2c is a metastasis susceptibility gene in breast cancer
TLDR
It is found that changing the expression of the gene Rnaseh2c changed the number of metastases that developed in the lungs of tumor-bearing mice and may help inform the understanding of AGS and RNase H2 in cancer. Expand
Aicardi-Goutières syndrome gene Rnaseh2c is a metastasis susceptibility gene in breast cancer
TLDR
An important novel, non-enzymatic role for RNASEH2C during breast cancer progression is suggested and Rnaseh2c is added to a panel of genes that together could determine patients with high risk for metastasis. Expand
...
1
2
3
4
5
...

References

SHOWING 1-10 OF 52 REFERENCES
Genomewide scan for prostate cancer-aggressiveness loci.
TLDR
It is suggested that candidate regions on chromosomes 5q, 7q, and 19q give evidence for linkage to PCa-aggressiveness genes, and that one or more of these regions may contain genes that influence the progression of PCa from latent to invasive disease. Expand
Germline Genetic Variation Modulates Tumor Progression and Metastasis in a Mouse Model of Neuroendocrine Prostate Carcinoma
TLDR
These experiments conclusively demonstrate that the introduction of germline variation by breeding modulates tumor growth, local metastasis burden, and distant metastasis frequency in this model of NEPC. Expand
Synergy of p53 and Rb deficiency in a conditional mouse model for metastatic prostate cancer.
TLDR
The studies show a critical role for p53 and Rb deficiency in prostate carcinogenesis and identify likely secondary genetic alterations and the new genetically defined model should be particularly valuable for providing new molecular insights into the pathogenesis of human prostate cancer. Expand
Integrative genomic profiling of human prostate cancer.
TLDR
Analysis of genomic and clinical outcome data from 218 prostate cancer tumors revealed that copy-number alterations robustly define clusters of low- and high-risk disease beyond that achieved by Gleason score. Expand
Androgen-Independent Prostate Cancer Is a Heterogeneous Group of Diseases
TLDR
Metastatic hormone-refractory prostate cancer has a heterogeneous morphology, immunophenotype, and genotype, demonstrating that “metastatic disease” is a group of diseases even within the same patient. Expand
Pathologic progression of autochthonous prostate cancer in the TRAMP model
TLDR
A standardized histologic grading system is presented to designate low and high grade prostatic intraepithelial neoplasia and well, moderate, and poorly differentiated prostate adenocarcinoma and it is reported that phenotypic variability in tumor and pathologic progression in TRAMP occurs as a function of genetic background. Expand
Identification of 23 new prostate cancer susceptibility loci using the iCOGS custom genotyping array
TLDR
On the basis of combined risks conferred by the new and previously known risk loci, the top 1% of the risk distribution has a 4.7-fold higher risk than the average of the population being profiled. Expand
Genome-wide association study of prostate cancer identifies a second risk locus at 8q24
TLDR
Observations indicate the presence of at least two independent loci within 8q24 that contribute to prostate cancer in men of European ancestry, and it is estimated that the population attributable risk of the new locus, marked by rs6983267, is higher than the locus marked byrs1447295. Expand
Neuroendocrine prostate cancer: subtypes, biology, and clinical outcomes.
TLDR
Clinically, small cell prostate cancer and NEPC are often manifested by the presence of visceral or large soft tissue metastatic disease, a disproportionately low serum prostate-specific antigen level relative to the overall burden of disease, and a limited response to targeting of the androgen signaling axis. Expand
Androgen-independent prostate cancer progression in the TRAMP model.
TLDR
It is demonstrated that prostate cancer in the TRAMP model is heterogeneous with respect to androgen dependence as early as 12 weeks of age; therefore, early androgen ablation may have a variable impact on progression in an individual mouse. Expand
...
1
2
3
4
5
...